Compare BANL & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BANL | ICU |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 15.6M |
| IPO Year | 2022 | 2021 |
| Metric | BANL | ICU |
|---|---|---|
| Price | $3.35 | $2.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.9K | ★ 201.3K |
| Earning Date | 08-18-2026 | 11-12-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,234,000.00 |
| Revenue This Year | N/A | $62.07 |
| Revenue Next Year | N/A | $46.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.27 | $0.22 |
| 52 Week High | $16.40 | $5.38 |
| Indicator | BANL | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 33.49 | 37.13 |
| Support Level | $0.36 | $2.33 |
| Resistance Level | $5.18 | $2.82 |
| Average True Range (ATR) | 0.35 | 0.41 |
| MACD | 0.05 | -0.10 |
| Stochastic Oscillator | 27.50 | 3.27 |
CBL International Ltd is a marine fuel logistics company that provides a one-stop solution for vessel refueling. In the bunkering industry, it is referred to as a bunkering facilitator. It facilitates vessel refueling between ship operators and local physical distributors/traders by purchasing marine fuel, including fossil fuel and alternative fuel, from its suppliers and arranging for the suppliers to deliver the fuel to the customers. The company's customer base comprises container liners, bulk carriers, and tankers. Geographically, the company generates a majority of its revenue from China, followed by Hong Kong, Malaysia, Singapore, South Korea, and other regions.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.